Correlation Between Bristol-Myers Squibb and MaxCyte
Can any of the company-specific risk be diversified away by investing in both Bristol-Myers Squibb and MaxCyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol-Myers Squibb and MaxCyte into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bristol Myers Squibb and MaxCyte, you can compare the effects of market volatilities on Bristol-Myers Squibb and MaxCyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol-Myers Squibb with a short position of MaxCyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol-Myers Squibb and MaxCyte.
Diversification Opportunities for Bristol-Myers Squibb and MaxCyte
-0.72 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Bristol-Myers and MaxCyte is -0.72. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and MaxCyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on MaxCyte and Bristol-Myers Squibb is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with MaxCyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of MaxCyte has no effect on the direction of Bristol-Myers Squibb i.e., Bristol-Myers Squibb and MaxCyte go up and down completely randomly.
Pair Corralation between Bristol-Myers Squibb and MaxCyte
Assuming the 90 days horizon Bristol Myers Squibb is expected to generate 1.06 times more return on investment than MaxCyte. However, Bristol-Myers Squibb is 1.06 times more volatile than MaxCyte. It trades about 0.04 of its potential returns per unit of risk. MaxCyte is currently generating about -0.02 per unit of risk. If you would invest 86,229 in Bristol Myers Squibb on September 2, 2024 and sell it today you would earn a total of 14,326 from holding Bristol Myers Squibb or generate 16.61% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 75.4% |
| Values | Daily Returns |
Bristol Myers Squibb vs. MaxCyte
Performance |
| Timeline |
| Bristol Myers Squibb |
| MaxCyte |
Bristol-Myers Squibb and MaxCyte Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Bristol-Myers Squibb and MaxCyte
The main advantage of trading using opposite Bristol-Myers Squibb and MaxCyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol-Myers Squibb position performs unexpectedly, MaxCyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MaxCyte will offset losses from the drop in MaxCyte's long position.| Bristol-Myers Squibb vs. Novartis AG | Bristol-Myers Squibb vs. Bayer AG | Bristol-Myers Squibb vs. Astellas Pharma | Bristol-Myers Squibb vs. Roche Holding AG |
| MaxCyte vs. Sight Sciences | MaxCyte vs. CVRx Inc | MaxCyte vs. Neuropace | MaxCyte vs. Rapid Micro Biosystems |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Complementary Tools
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |